Lenox Wealth Advisors’s Regeneron Pharmaceuticals REGN Stock Holding History

Lenox Wealth Advisors’s Portfolio REGN Stock Details REGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	$53K	Sell	72 -3	-4%	-$1.9K	0.01%	241
2021 Q4	$47K	Buy	75 +73	+3,650%	+$44.9K	0.01%	267
2021 Q3	$1K	Buy	2 +1	+100%	+$621	﹤0.01%	689
2021 Q2	$1K	Hold	1	–	–	﹤0.01%	678
2021 Q1	$0	Buy	+1	New	+$487	﹤0.01%	744
2019 Q4	–	Sell	-14	Closed	-$4K	–	800
2019 Q3	$4K	Sell	14 -24	-63%	-$7.1K	﹤0.01%	425
2019 Q2	$12K	Sell	38 -21	-36%	-$6.99K	﹤0.01%	268
2019 Q1	$24K	Sell	59 -4	-6%	-$1.65K	﹤0.01%	186
2018 Q4	$24K	Hold	63	–	–	0.01%	182
2018 Q3	$25K	Sell	63 -19	-23%	-$7.23K	0.01%	190
2018 Q2	$28K	Buy	82 +12	+17%	+$3.75K	0.01%	209
2018 Q1	$24K	Buy	70 +52	+289%	+$18.1K	0.01%	248
2017 Q4	$7K	Buy	+18	New	+$7.29K	﹤0.01%	194
2016 Q1	–	Sell	-7	Closed	-$4K	–	382
2015 Q4	$4K	Buy	+7	New	+$3.79K	﹤0.01%	262

Other funds holding REGN

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Lenox Wealth Advisors's REGN Position: Q1 2022 in Review

Lenox Wealth Advisors reduced its Regeneron Pharmaceuticals (REGN) stake by 4% in Q1 2022, selling an estimated $1.9K and leaving 72 shares worth $53K. The position accounts for 0.01% of the portfolio, ranked #241.

Lenox Wealth Advisors first reported a position in REGN in Q4 2015 and has held it in 14 quarters since. 1,095 funds tracked by Wall St. Rank hold REGN as of Q1 2022.

Lenox Wealth Advisors held 72 shares of Regeneron Pharmaceuticals worth $53K as of Q1 2022.
Lenox Wealth Advisors sold 3 Regeneron Pharmaceuticals shares in Q1 2022, an estimated $1.9K.
Regeneron Pharmaceuticals made up 0.01% of Lenox Wealth Advisors's portfolio in Q1 2022, its #241 holding.
Lenox Wealth Advisors first reported a position in Regeneron Pharmaceuticals in Q4 2015 and has held it in 14 quarters since.
1,095 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q1 2022.

Based on Lenox Wealth Advisors's 13F filing for Q1 2022, filed 14 Apr 2022.